Page last checked
Synthetic pentadecapeptide (research compound) · safety
No controlled human trial has published a side-effect rate or safety profile for BPC-157. Here is what is actually known instead, and what that gap does and does not tell you.
BPC-157 is a lab-made peptide, fifteen amino acids long, copied from one short stretch of a protein found in human stomach juice. People take it hoping to heal faster — tendon and ligament injuries, muscle tears, and gut conditions such as inflammatory bowel disease.
Nearly all of that comes from rats and mice. Three small reports describe people receiving it, none with a comparison group, and between them they cover fewer than 30 subjects. None of the three tested a healing injury, and none used an injection under the skin.
No completed controlled human trial has shown which dose works for BPC-157. The range people report using is not a study result, tested schedule or recommendation.
no human dose shown to work
Common reactions listed
None published
Serious reactions listed
None published
Boxed warning
No label exists
Strongest source
no human dose shown to work
Because no controlled human safety profile has been published for this compound, there is no evidence-based list of warning signs specific to it. That removes the early warning, not the risk. Any new, severe or lasting symptom belongs with a clinician. Tell them exactly what was taken.
There is no side-effect table on this page because there is no controlled human safety profile to build one from — and an empty table is more honest than a plausible one.
A published side-effect profile is not a summary of what people have noticed. It is the output of a specific process: a controlled trial enrolls a defined group and records every event, whether or not it looks related. It compares those rates against a control group, then publishes the result against a plan registered before the first dose. Where that process has not produced a profile, the output does not exist. Nothing stands in for it — not seller literature, not clinic protocols, not forum threads.
So the absence says something about the evidence, not about the compound. A profile nobody has measured is not a clean profile; it is an unmeasured one. Those two get confused constantly, and the confusion always runs in the direction that flatters the compound.
It is worth being blunt about the asymmetry. Rare and serious reactions are exactly the ones that scattered, self-reported experience is worst at catching. They are uncommon by definition, they can take time to appear, and they are easy to blame on something else.
The people who get them are also the least likely to come back and post an update. What shows up first in an unstudied compound is the mild and the immediate. That is a fact about how the reports get collected, not evidence about the compound.
The missing profile takes the rest of the scaffolding with it. With no approved label there is no list of who should avoid it, no documented interactions and no monitoring plan. There is no ceiling dose, and no channel carrying reports back to a regulator. Anyone taking an unapproved compound is outside all of those at once — and silence from a system that does not exist is not reassurance.
The published human evidence covers fewer than thirty people. The three small reports had no comparison groups and cannot produce a reliable safety profile.
The published human evidence consists of three small reports: a case series in twelve women, a two-person infusion check and a review of knee-joint injections. None had a control group, and all three came from the same clinician and journal.
None used an injection under the skin, which is the route these vials serve. So even the harms somebody did look for, they looked for in people taking the compound another way.
FDA’s current page lists BPC-157 among substances whose compounding nominations were withdrawn. The agency also says it lacks enough information to know whether the drug would cause harm in people.
That is different from a finding of harm. It is also a long way from reassurance. Both nominators withdrew their requests, while FDA still chose to review the available record.
Measured clearance puts this peptide out of the body in under half an hour. People credit it with effects lasting hours to days. Nobody has published a mechanism that closes the gap.
On a safety page that matters more than it looks. If a compound clears that fast and still gets credit for lasting effects, then nobody has identified what actually does the work. A mechanism nobody has identified carries a risk nobody has measured.
Four readings of an empty safety record go around. Each one turns a missing measurement into reassurance.
| The claim | What the evidence shows |
|---|---|
| Nothing serious has been reported. | Nothing has been systematically collected. A report needs a system that receives it, strips out duplicates and counts it. For an unapproved compound there is no such system, so silence is what you would get either way. |
| The studies look clean. | The published work is overwhelmingly in animals or too small and uncontrolled to produce a safety rate. Animal findings do not carry over to people at human doses over human timescales, and uncontrolled exposure supplies no comparison group or denominator. |
| People have used it for years. | Informal use is not monitoring. Years of unmeasured use produce familiarity and confidence. They do not produce a denominator, a comparison group, or a rate. |
| People seem to handle it well. | How well people handle a compound is measured against a control group. Without that comparison, the claim is only the writer’s impression. |
No human safety profile has been published for this compound. If that changes, the results should be reported with the study size, comparison group and citation—not filled in with assumptions.
No controlled human study has published a side-effect rate or safety profile. That describes the missing evidence, not the compound: unmeasured does not mean safe.
The published human evidence cannot answer that either way. Reliable safety estimates need systematic collection, a total number treated and a comparison group; none is available here.
Take the symptom to a clinician, and say exactly what was taken, how much and for how long. Clinicians assess symptoms without needing an approved label to exist, and leaving out the detail removes the one piece of context that changes what they look for.
The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.
BPC-157 dosing evidence, without an approved schedule
What BPC-157 is, how it is used, and what has been studied
BPC-157 vial and water to an exact amount
Take the BPC-157 arithmetic to any other vial
What the FDA has published on BPC-157
All the pages BPC-157 is compared with
Why some BPC-157 values are missing on purpose